Harvard Apparatus Regenerative Tech Inc  

(Public, NASDAQ:HART)   Watch this stock  
Find more results for JOHN F. MCNAUGHTON
2.67
+0.11 (4.30%)
May 4 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.25 - 2.69
52 week 1.85 - 10.82
Open 2.44
Vol / Avg. 65,301.00/44,652.00
Mkt cap 28.29M
P/E     -
Div/yield     -
EPS -1.41
Shares 10.07M
Beta     -
Inst. own 33%
May 7, 2015
Q1 2015 Harvard Apparatus Regenerative Technology Inc Earnings Call - 11:00AM EDT - Add to calendar
May 7, 2015
Q1 2015 Harvard Apparatus Regenerative Technology Inc Earnings Release - 9:30AM EDT - Add to calendar
Mar 19, 2015
Q4 2014 Harvard Apparatus Regenerative Technology Inc Earnings Call - Webcast
Mar 19, 2015
Q4 2014 Harvard Apparatus Regenerative Technology Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -6315.56% -11893.55%
Operating margin -6315.56% -11889.25%
EBITD margin - -11498.92%
Return on average assets -137.21% -99.34%
Return on average equity -150.09% -105.03%
Employees 24 -
CDP Score - -

Address

84 October Hill Rd Ste 11
HOLLISTON, MA 01746-1371
United States - Map
+1-508-8938999 (Phone)
+1-302-6745266 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Harvard Apparatus Regenerative Technology, Inc. is clinical stage regenerative medicine company developing life-saving medical devices. The Company�s products include Hollow Organ Bioreactors, Solid Organ Bioreactors, Scaffolds, and Clinical Infusion Pump. The Company�s first products are a bioreactor and a synthetic scaffold that can be used by surgeons to create a replacement trachea, or airway, for patients who need an airway transplant. Its bioreactor technology has been used in six human airway transplant surgeries. Its r products are in development. The Company�s products address the critical challenges to trachea transplant, the shortage of suitable donor tracheas. The Company is a wholly owned subsidiary Harvard Bioscience Inc. In October 2013, Harvard Bioscience Inc announced the spin-off of its wholly owned regenerative medicine device subsidiary, Harvard Apparatus Regenerative Technology, Inc.

Officers and directors

John F. Kennedy Chairman of the Board
Age: 66
Bio & Compensation  - Reuters
Thomas McNaughton Jr. Interim Chief Executive Officer, Chief Financial Officer
Age: 54
Bio & Compensation  - Reuters
Saverio La Francesca M.D. Chief Medical Officer
Bio & Compensation  - Reuters
David M. Green Director
Age: 50
Bio & Compensation  - Reuters
John J. Canepa Independent Director
Age: 59
Bio & Compensation  - Reuters
James J. McGorry Independent Director
Age: 59
Bio & Compensation  - Reuters
Thomas H. Robinson Independent Director
Age: 56
Bio & Compensation  - Reuters